A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer

Shin, Sung-Young; Centenera, Margaret M.; Hodgson, Joshua T.; Nguyen, Elizabeth V.; Butler, Lisa M.; Daly, Roger J.; Nguyen, Lan K.

doi:10.3389/fmolb.2023.1094321

Cited by 5 publications

(2 citation statements)

References 112 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that therapy-oriented clinical trials based on Hopfield, Boolean, and (epi)genetic landscape modeling are still lacking. However, the effort of modeling integration into clinical pipelines is ongoing [37][38][39][40][41].…”

Section: Ergodicity and Cancermentioning

confidence: 99%

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

Carels,

Sgariglia,

Junior

et al. 2023

IJMS

View full text Add to dashboard Cite

We describe a strategy for the development of a rational approach of neoplastic disease therapy based on the demonstration that scale-free networks are susceptible to specific attacks directed against its connective hubs. This strategy involves the (i) selection of up-regulated hubs of connectivity in the tumors interactome, (ii) drug repurposing of these hubs, (iii) RNA silencing of non-druggable hubs, (iv) in vitro hub validation, (v) tumor-on-a-chip, (vi) in vivo validation, and (vii) clinical trial. Hubs are protein targets that are assessed as targets for rational therapy of cancer in the context of personalized oncology. We confirmed the existence of a negative correlation between malignant cell aggressivity and the target number needed for specific drugs or RNA interference (RNAi) to maximize the benefit to the patient’s overall survival. Interestingly, we found that some additional proteins not generally targeted by drug treatments might justify the addition of inhibitors designed against them in order to improve therapeutic outcomes. However, many proteins are not druggable, or the available pharmacopeia for these targets is limited, which justifies a therapy based on encapsulated RNAi.

show abstract

Section: Ergodicity and Cancermentioning

confidence: 99%

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

Carels,

Sgariglia,

Junior

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…• Serum Uric Acid: Elevated uric acid levels have been associated with endothelial dysfunction, a hallmark feature of pre-eclampsia. [9] • Lactate Dehydrogenase (LDH): Increased LDH levels may indicate tissue damage and organ dysfunction, which can occur in severe pre-eclampsia. • Alkaline Phosphatase (ALP): ALP is an enzyme found in the liver and bones, and elevated levels may suggest liver involvement in pre-eclampsia.…”

Section: Overview Of Various Biomarkers Studied For Pre-eclampsia Dia...mentioning

confidence: 99%

Diagnostic Serum Markers for Pre-eclampsia – An Overview

2023

IJFMR

View full text Add to dashboard Cite

Pre-eclampsia, a hypertensive disorder of pregnancy, remains a major global health concern due to its potential for adverse maternal and fetal outcomes. Early and accurate diagnosis is crucial for effective management. Serum markers have emerged as valuable tools in this regard, offering insights into the pathophysiology and severity of pre-eclampsia. This comprehensive review explores the diagnostic utility of serum markers in pre-eclampsia. We examine the physiological basis and rationale for using specific markers, including serum uric acid, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), 24-hour urine protein, and serum prolactin, among others. Additionally, we discuss the challenges and limitations associated with these markers, considering factors influencing marker levels and diagnostic interpretation. Serum markers, when integrated into clinical practice, enhance early diagnosis, risk stratification, and individualized care for pregnant individuals. They facilitate the identification of high-risk cases, prompt timely interventions, and reduce maternal and fetal complications associated with pre-eclampsia. Furthermore, clinical guidelines from authoritative bodies endorse the incorporation of serum markers in pre-eclampsia assessment. Serum markers represent a promising frontier in pre-eclampsia diagnosis, offering the potential to revolutionize prenatal care. While challenges exist, ongoing research, standardization efforts, and larger-scale studies will further refine the clinical utility of serum markers. Their integration aligns with established guidelines and holds the promise of improving maternal and fetal outcomes, making a significant impact on global maternal healthcare.

show abstract

Developing a nanomaterial-based 3D-printed platform: Application as a cancer aptasensor via detection of heat shock protein 90 (HSP90)

Negahdary,

do Lago,

Gutz

et al. 2024

Sensors and Actuators B: Chemical

View full text Add to dashboard Cite

A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer

Cited by 5 publications

References 112 publications

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases

Diagnostic Serum Markers for Pre-eclampsia – An Overview

Developing a nanomaterial-based 3D-printed platform: Application as a cancer aptasensor via detection of heat shock protein 90 (HSP90)

Contact Info

Product

Resources

About